February 22, 2016
1 min read
Save

Infectious Disease News prepares for CROI 2016

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

BOSTON — Infectious Disease News and Healio.com/ID will offer live coverage from the annual Conference on Retroviruses and Opportunistic Infections, or CROI, held today through Feb. 25. Sponsored by the International Antiviral Society-USA, the conference will feature experts from around the world speaking on new research related to HIV and other infectious diseases.

“CROI is with little doubt the most anticipated annual scientific conference for the field of viral diseases, particularly HIV and HCV,” Infectious Disease News Chief Medical Editor Paul A. Volberding, MD, said. “The meeting focuses on basic, clinical and translational investigation but has substantial interest in the prevention science community, especially given recent advances in pre-exposure prophylaxis and the role of HIV treatment in preventing transmission. There will be a number of presentations covering progress in understanding HIV persistence and efforts to develop a cure.

Paul A. Volberding

“In HCV, there will be discussions of advances in treatments that cover all HCV types, and a direction in simplifying treatment decisions that could help expand the fraction of the very large infected population accessing curative treatments. As always, we look forward to learning at CROI and in getting that information as widely disseminated as possible.”

In addition to breaking news, the Infectious Disease News staff will conduct onsite video interviews with experts to gain their perspectives on some of the presentations at the conference. Readers also can expect news wires featuring the conference’s top headlines. Visit www.healio.com/ID throughout the week to read the latest news.

Disclosure: Volberding reports no relevant financial disclosures.